Center-Authored Papers

Filters: Author is Verstovsek, Srdan  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, Faderl S, O'Brien S, Wierda W, Pierce S et al..  2017.  Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab.. Blood. 129(10):1275-1283. Abstract
D
Deininger M, Radich J, Burn TC, Huber R, Paranagama D, Verstovsek S.  2015.  The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis.. Blood. 126(13):1551-1554. Abstract
G
Gupta V, Gotlib J, Radich JP, Kröger NM, Rondelli D, Verstovsek S, Deeg HJ.  2014.  JAK Inhibitors and Allogeneic Stem Cell Transplantation for Myelofibrosis.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. Abstract
M
Mesa R, Jamieson C, Bhatia R, Deininger MW, Gerds AT, Gojo I, Gotlib J, Gundabolu K, Hobbs G, Klisovic RB et al..  2016.  Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.. Journal of the National Comprehensive Cancer Network : JNCCN. 14(12):1572-1611. Abstract
R
Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J, Pierce S, Blamble D, Estrov Z, Wierda W et al..  2009.  Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(4):504-10. Abstract
S
Stein BL, Gotlib J, Arcasoy M, Nguyen MH, Shah N, Moliterno A, Jamieson C, Pollyea DA, Scott B, Wadleigh M et al..  2015.  Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.. Journal of the National Comprehensive Cancer Network : JNCCN. 13(4):424-34. Abstract
T
Tefferi A, Verstovsek S, Barosi G, Passamonti F, Roboz GJ, Gisslinger H, Paquette RL, Cervantes F, Rivera CE, Deeg HJ et al..  2009.  Pomalidomide is active in the treatment of anemia associated with myelofibrosis.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(27):4563-9. Abstract
U
Ustun C, Gotlib J, Popat U, Artz A, Litzow M, Reiter A, Nakamura R, Kluin-Nelemans HC, Verstovsek S, Gajewski J et al..  2016.  Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 22(8):1348-1356. Abstract
V
Verstovsek S, Odenike O, Singer JW, Granston T, Al-Fayoumi S, Deeg HJ.  2016.  Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies.. Journal of hematology & oncology. 9(1):137. Abstract